Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer

Seer-medicare trends 1991 to 1999

Steven B. Zeliadt, Arnold L. Potosky, Ruth Etzioni, Scott D. Ramsey, David F. Penson

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

To assess trends in the initial care of nonmetastatic prostate cancer, including the use of primary and adjuvant androgen deprivation therapy (ADT), using population-based treatment claims from 1991 to 1999. We used a database linking the Surveillance, Epidemiology, and End Results (SEER) registry with Medicare claims to extract treatment information for 90,128 men aged 65 years and older, who were newly diagnosed with nonmetastatic prostate cancer. The use of aggressive therapy has increased among white men over time; but aggressive therapy has recently declined among African-American men. Accounting for age, grade, socioeconomic status, and comorbidity, African-American men were 26% less likely to receive aggressive therapy than white men (odds ratio 0.74; 95% confidence interval 0.70 to 0.79). The use of ADT has increased substantially in both the primary and the adjuvant settings. By 1999, 45.6% of white men and 35.8% of African-American men who selected conservative management received primary ADT; among men treated with external beam radiotherapy, the proportion receiving adjuvant ADT was 53.7% for white men and 42.4% for African-American men (P <0.001). Racial differences in the use of aggressive and conservative therapies are increasing. ADT is becoming a widely adopted component of initial treatment for localized prostate cancer. It is crucial to understand the impact of treatment patterns, including the increased use of ADT, on patient survival, morbidity, and costs of care.

Original languageEnglish (US)
Pages (from-to)1171-1176
Number of pages6
JournalUrology
Volume64
Issue number6
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

Medicare
Prostatic Neoplasms
Androgens
African Americans
Therapeutics
Social Class
Registries
Comorbidity
Epidemiology
Radiotherapy
Odds Ratio
Databases
Confidence Intervals
Morbidity

ASJC Scopus subject areas

  • Urology

Cite this

Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer : Seer-medicare trends 1991 to 1999. / Zeliadt, Steven B.; Potosky, Arnold L.; Etzioni, Ruth; Ramsey, Scott D.; Penson, David F.

In: Urology, Vol. 64, No. 6, 01.12.2004, p. 1171-1176.

Research output: Contribution to journalArticle

Zeliadt, Steven B. ; Potosky, Arnold L. ; Etzioni, Ruth ; Ramsey, Scott D. ; Penson, David F. / Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer : Seer-medicare trends 1991 to 1999. In: Urology. 2004 ; Vol. 64, No. 6. pp. 1171-1176.
@article{1e26a69099ff40348ce97c2decf16ab6,
title = "Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: Seer-medicare trends 1991 to 1999",
abstract = "To assess trends in the initial care of nonmetastatic prostate cancer, including the use of primary and adjuvant androgen deprivation therapy (ADT), using population-based treatment claims from 1991 to 1999. We used a database linking the Surveillance, Epidemiology, and End Results (SEER) registry with Medicare claims to extract treatment information for 90,128 men aged 65 years and older, who were newly diagnosed with nonmetastatic prostate cancer. The use of aggressive therapy has increased among white men over time; but aggressive therapy has recently declined among African-American men. Accounting for age, grade, socioeconomic status, and comorbidity, African-American men were 26{\%} less likely to receive aggressive therapy than white men (odds ratio 0.74; 95{\%} confidence interval 0.70 to 0.79). The use of ADT has increased substantially in both the primary and the adjuvant settings. By 1999, 45.6{\%} of white men and 35.8{\%} of African-American men who selected conservative management received primary ADT; among men treated with external beam radiotherapy, the proportion receiving adjuvant ADT was 53.7{\%} for white men and 42.4{\%} for African-American men (P <0.001). Racial differences in the use of aggressive and conservative therapies are increasing. ADT is becoming a widely adopted component of initial treatment for localized prostate cancer. It is crucial to understand the impact of treatment patterns, including the increased use of ADT, on patient survival, morbidity, and costs of care.",
author = "Zeliadt, {Steven B.} and Potosky, {Arnold L.} and Ruth Etzioni and Ramsey, {Scott D.} and Penson, {David F.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.urology.2004.07.037",
language = "English (US)",
volume = "64",
pages = "1171--1176",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer

T2 - Seer-medicare trends 1991 to 1999

AU - Zeliadt, Steven B.

AU - Potosky, Arnold L.

AU - Etzioni, Ruth

AU - Ramsey, Scott D.

AU - Penson, David F.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - To assess trends in the initial care of nonmetastatic prostate cancer, including the use of primary and adjuvant androgen deprivation therapy (ADT), using population-based treatment claims from 1991 to 1999. We used a database linking the Surveillance, Epidemiology, and End Results (SEER) registry with Medicare claims to extract treatment information for 90,128 men aged 65 years and older, who were newly diagnosed with nonmetastatic prostate cancer. The use of aggressive therapy has increased among white men over time; but aggressive therapy has recently declined among African-American men. Accounting for age, grade, socioeconomic status, and comorbidity, African-American men were 26% less likely to receive aggressive therapy than white men (odds ratio 0.74; 95% confidence interval 0.70 to 0.79). The use of ADT has increased substantially in both the primary and the adjuvant settings. By 1999, 45.6% of white men and 35.8% of African-American men who selected conservative management received primary ADT; among men treated with external beam radiotherapy, the proportion receiving adjuvant ADT was 53.7% for white men and 42.4% for African-American men (P <0.001). Racial differences in the use of aggressive and conservative therapies are increasing. ADT is becoming a widely adopted component of initial treatment for localized prostate cancer. It is crucial to understand the impact of treatment patterns, including the increased use of ADT, on patient survival, morbidity, and costs of care.

AB - To assess trends in the initial care of nonmetastatic prostate cancer, including the use of primary and adjuvant androgen deprivation therapy (ADT), using population-based treatment claims from 1991 to 1999. We used a database linking the Surveillance, Epidemiology, and End Results (SEER) registry with Medicare claims to extract treatment information for 90,128 men aged 65 years and older, who were newly diagnosed with nonmetastatic prostate cancer. The use of aggressive therapy has increased among white men over time; but aggressive therapy has recently declined among African-American men. Accounting for age, grade, socioeconomic status, and comorbidity, African-American men were 26% less likely to receive aggressive therapy than white men (odds ratio 0.74; 95% confidence interval 0.70 to 0.79). The use of ADT has increased substantially in both the primary and the adjuvant settings. By 1999, 45.6% of white men and 35.8% of African-American men who selected conservative management received primary ADT; among men treated with external beam radiotherapy, the proportion receiving adjuvant ADT was 53.7% for white men and 42.4% for African-American men (P <0.001). Racial differences in the use of aggressive and conservative therapies are increasing. ADT is becoming a widely adopted component of initial treatment for localized prostate cancer. It is crucial to understand the impact of treatment patterns, including the increased use of ADT, on patient survival, morbidity, and costs of care.

UR - http://www.scopus.com/inward/record.url?scp=10644262092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644262092&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2004.07.037

DO - 10.1016/j.urology.2004.07.037

M3 - Article

VL - 64

SP - 1171

EP - 1176

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -